Jefferies Hikes Veeva Systems (VEEV) Price Target to $335, Maintains Buy Rating

On June 2, Jefferies analysts increased the price target for Veeva Systems Inc. (NYSE:VEEV) to $335 from $280 while maintaining a ‘Buy’ rating. The price target adjustment follows the company’s strong performance in the first quarter.

Jefferies Hikes Veeva Systems (VEEV) Price Target to $335

A healthcare professional in a meeting with a patient discussing care options using digital technology.

According to Jefferies analysts, Veeva Systems was one of the bright spots in the sector, based on the solid first quarter fiscal 2026 results. The better-than-expected results came as the company benefited from strong demand in its commercial operations.

Veeva Systems shrugged challenging conditions in the pharmaceutical supply chain sector to deliver robust margins and growth in commercial operations. It achieved a 75.5% gross profit margin in the quarter, as revenue totaled $2.85 billion. Strong performance in the Crossix and Vault CRM was one of the catalysts behind the solid first-quarter results. The research and development segment remained resilient despite pressure due to macroeconomic uncertainties and policy changes.

Veeva Systems is a healthcare company that provides software, data, and services to the life sciences industry. Its solutions support various functions, including R&D, safety, and commercial activities.

While we acknowledge the potential of Veeva Systems Inc. (NYSE:VEEV) as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than VEEV and that has 100x upside potential, check out our report about the cheapest AI stock.

READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.

Disclosure: None.